Early treatment with Ataluren of a 2-year-old boy with nonsense mutation Duchenne dystrophy

Ilaria Bitetti 1, Cinzia Mautone 1, Marianna Bertella 2, Maria Rosaria Manna 2, Antonio Varone 1

1 Pediatric Neurology, Santobono-Pausilipon Children’s Hospital, Naples, Italy; 2 Neurorehabilitation Unit, Santobono-Pausilipon Children’s Hospital, Naples, Italy

DOI 10.36185/2532-1900-062

Duchenne muscular dystrophy (DMD) is an X-linked myopathy caused by mutations, in most cases deletions and duplications, in the dystrophin gene. Point mutations account for 13% and stop codon mutations are even rarer. Ataluren was approved for the treatment of DMD caused by nonsense mutations in 2014, and several clinical trials documented its efficacy and safety. However, few real-life experience data is available, especially in pediatric age. We report the case of a 2-year- ambulant child affected by DMD caused by the stop-codon mutation c.10801C > T, p.Gln3601X in exon 76, who was early treated with Ataluren at a dosage of 40 mg/kg/die, and presented a rapid improvement in both muscle strength and cognitive and social skills.

Scarica il PDF